How the gene regulator SIN3a affects lung blood vessel cells in pulmonary hypertension
Role of Epigenetic Regulator SIN3a in Pulmonary Endothelial Cells
This project looks at whether restoring a gene regulator called SIN3a in lung blood vessel cells can help people with pulmonary arterial hypertension.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11192364 on NIH RePORTER |
What this research studies
Pulmonary arterial hypertension (PAH) causes lung blood vessel cells to malfunction and narrow the vessels, with loss of BMPR2 function being a key problem. Scientists will study how the epigenetic regulator SIN3a controls BMPR2 in pulmonary artery endothelial cells using cell experiments and animal models. They will examine DNA methylation and gene activity to understand how SIN3a leads to BMPR2 changes and endothelial dysfunction. The team will also test a targeted delivery method to restore SIN3a function in lung endothelial cells as a possible way to reverse vascular damage.
Who could benefit from this research
Good fit: People with pulmonary arterial hypertension, especially those with BMPR2 mutations or evidence of endothelial cell dysfunction, would be the most relevant candidates for related future therapies.
Not a fit: Patients with other types of pulmonary hypertension, very advanced disease, or lung problems unrelated to BMPR2 signaling may not benefit from this approach.
Why it matters
Potential benefit: If successful, this work could point to new treatments that restore BMPR2 signaling and improve blood flow in the lungs for people with PAH.
How similar studies have performed: Prior work showed SIN3a affects BMPR2 silencing in smooth muscle cells, but applying that finding to lung endothelial cells and testing targeted restoration is largely new.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Hadri, Lahouaria — Icahn School of Medicine at Mount Sinai
- Study coordinator: Hadri, Lahouaria
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.